Loading
Liver Disease Diagnosis and Treatment · Journal article
Journal of the Science of Food and Agriculture · September 7, 2026
Raises a question worth testing. It does not answer one.
This preclinical study in C57BL/6 mice identifies a putative 'gut microbiota-primary bile acid' mechanism by which oral alpha-lipoic acid (ALA) may reduce hepatic steatosis and inflammation induced by high-fat diet. The work is mechanistic and exploratory, establishing a biological hypothesis but providing no direct evidence of clinical efficacy or safety in humans.
Single-species preclinical mechanistic study (mouse model). C57BL/6 mice; treatment group (HFD + ALA) and control group (HFD alone) status and group sizes not specified in source text.. Intervention: Alpha-lipoic acid (ALA) supplementation at 60 mg/kg/day for 12 weeks, administered during high-fat diet feeding.. Compared with: High-fat diet without ALA supplementation for 12 weeks..
ALA at 60 mg/kg/day for 12 weeks significantly attenuated HFD-induced obesity, dyslipidemia, insulin resistance, and hepatic injury (steatosis, apoptosis, oxidative stress) in mice, without altering caloric intake. ALA restored intestinal barrier function by up-regulating tight junction proteins (Occludin, ZO-1) and mucin (Muc2). 16S rRNA sequencing showed ALA selectively enriched beneficial gut bacteria (Akkermansia, Lactobacillus) and reversed HFD-induced depletion of primary bile acids including cholic acid (CA) and chenodeoxycholic acid (CDCA).
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study provides mechanistic insight into a potential pathway but does not provide evidence for or against the use of ALA in humans with metabolic dysfunction-associated steatotic liver disease. Human trials are required before clinical recommendations can be made.
This is a mechanistic study in a single animal model without human data, showing pathway elucidation rather than clinical evidence of efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
This study provides mechanistic insight into a potential pathway but does not provide evidence for or against the use of ALA in humans with metabolic dysfunction-associated steatotic liver disease. Human trials are required before clinical recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent global health concern with limited therapeutic options. Alpha-lipoic acid (ALA), a naturally occurring organosulfur compound with potent antioxidant activity, shows hepatoprotective potential, but its mechanisms along the gut-liver axis remain poorly understood. This study investigated whether ALA ameliorates high-fat diet (HFD)-induced MASLD by repairing the intestinal barrier and restoring gut microbiota-mediated primary bile acid (BA) signaling. RESULTS: In C57BL/6 mice fed an HFD with or without ALA supplementation (60 mg/kg/d) for 12 weeks, ALA significantly attenuated HFD-induced obesity, dyslipidemia, insulin resistance, and hepatic injury (steatosis, apoptosis, oxidative stress), without altering caloric intake. ALA restored intestinal barrier function by up-regulating tight junction proteins (Occludin, ZO-1) and mucin (Muc2), reducing systemic inflammation and metabolic endotoxemia. Integrated 16S rRNA sequencing and targeted BA metabolomics revealed that ALA selectively enriched beneficial gut bacteria (e.g., Akkermansia, Lactobacillus) and reversed HFD-induced depletion of primary BAs including cholic acid (CA) and chenodeoxycholic acid (CDCA). These restored primary BAs were positively correlated with the enriched microbial taxa. CONCLUSION: These findings elucidate a novel 'gut microbiota-primary bile acid' axis underlying the hepatoprotective effects of dietary ALA, supporting its potential as a functional food component or dietary supplement for MASLD management. © 2026 Society of Chemical Industry.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.